Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

The evolutionary origin of the Runx/CBFbeta transcription factors--studies of the most basal metazoans.

Sullivan JC, Sher D, Eisenstein M, Shigesada K, Reitzel AM, Marlow H, Levanon D, Groner Y, Finnerty JR, Gat U.

BMC Evol Biol. 2008 Aug 5;8:228. doi: 10.1186/1471-2148-8-228.

2.

RUNX regulates stem cell proliferation and differentiation: insights from studies of C. elegans.

Kagoshima H, Shigesada K, Kohara Y.

J Cell Biochem. 2007 Apr 1;100(5):1119-30. Review.

PMID:
17265434
3.

Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia.

Asou N, Yanagida M, Huang L, Yamamoto M, Shigesada K, Mitsuya H, Ito Y, Osato M.

Blood. 2007 May 1;109(9):4023-7. Epub 2007 Jan 23.

PMID:
17244685
4.

Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice.

Yamashita N, Osato M, Huang L, Yanagida M, Kogan SC, Iwasaki M, Nakamura T, Shigesada K, Asou N, Ito Y.

Br J Haematol. 2005 Nov;131(4):495-507.

PMID:
16281942
5.

The C. elegans RUNX transcription factor RNT-1/MAB-2 is required for asymmetrical cell division of the T blast cell.

Kagoshima H, Sawa H, Mitani S, B├╝rglin TR, Shigesada K, Kohara Y.

Dev Biol. 2005 Nov 15;287(2):262-73. Epub 2005 Oct 13.

6.

Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.

Yanagida M, Osato M, Yamashita N, Liqun H, Jacob B, Wu F, Cao X, Nakamura T, Yokomizo T, Takahashi S, Yamamoto M, Shigesada K, Ito Y.

Oncogene. 2005 Jun 30;24(28):4477-85.

PMID:
15856017
7.

Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11.

Shigesada K, van de Sluis B, Liu PP.

Oncogene. 2004 May 24;23(24):4297-307. Review.

PMID:
15156186
8.

Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera.

Huang G, Shigesada K, Wee HJ, Liu PP, Osato M, Ito Y.

Blood. 2004 Apr 15;103(8):3200-7. Epub 2003 Dec 24.

PMID:
15070703
9.

Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.

Matsuno N, Osato M, Yamashita N, Yanagida M, Nanri T, Fukushima T, Motoji T, Kusumoto S, Towatari M, Suzuki R, Naoe T, Nishii K, Shigesada K, Ohno R, Mitsuya H, Ito Y, Asou N.

Leukemia. 2003 Dec;17(12):2492-9.

PMID:
14562119
10.

Functional analysis of RUNX2 mutations in cleidocranial dysplasia: novel insights into genotype-phenotype correlations.

Yoshida T, Kanegane H, Osato M, Yanagida M, Miyawaki T, Ito Y, Shigesada K.

Blood Cells Mol Dis. 2003 Mar-Apr;30(2):184-93.

PMID:
12732182
11.

Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms.

Wee HJ, Huang G, Shigesada K, Ito Y.

EMBO Rep. 2002 Oct;3(10):967-74. Epub 2002 Sep 13.

12.

Functional analysis of RUNX2 mutations in Japanese patients with cleidocranial dysplasia demonstrates novel genotype-phenotype correlations.

Yoshida T, Kanegane H, Osato M, Yanagida M, Miyawaki T, Ito Y, Shigesada K.

Am J Hum Genet. 2002 Oct;71(4):724-38. Epub 2002 Aug 26.

13.

In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.

Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, Rossier C, Antonarakis SE, Israels S, McNicol A, Weiss H, Horwitz M, Scott HS.

Blood. 2002 Feb 15;99(4):1364-72.

PMID:
11830488
14.

Point mutations of the RUNx1/AML1 gene in sporadic and familial myeloid leukemias.

Osato M, Yanagida M, Shigesada K, Ito Y.

Int J Hematol. 2001 Oct;74(3):245-51. Review.

PMID:
11721958
15.

Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation.

Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y.

EMBO J. 2001 Feb 15;20(4):723-33.

16.

Mechanisms of transcriptional regulation by Runt domain proteins.

Wheeler JC, Shigesada K, Gergen JP, Ito Y.

Semin Cell Dev Biol. 2000 Oct;11(5):369-75. Review.

PMID:
11105901
17.
18.

[Molecular mechanisms of PEBP2/CBF as a master regulator of tissue-specific gene expression].

Shigesada K.

Tanpakushitsu Kakusan Koso. 2000 Jan;45(1):55-62. Review. Japanese. No abstract available.

PMID:
10643336
19.

Runt domains take the lead in hematopoiesis and osteogenesis.

Werner MH, Shigesada K, Ito Y.

Nat Med. 1999 Dec;5(12):1356-7. No abstract available.

PMID:
10581073
20.

Molecular insights into PEBP2/CBF beta-SMMHC associated acute leukemia revealed from the structure of PEBP2/CBF beta.

Goger M, Gupta V, Kim WY, Shigesada K, Ito Y, Werner MH.

Nat Struct Biol. 1999 Jul;6(7):620-3.

PMID:
10404215
21.

Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain.

Nagata T, Gupta V, Sorce D, Kim WY, Sali A, Chait BT, Shigesada K, Ito Y, Werner MH.

Nat Struct Biol. 1999 Jul;6(7):615-9.

PMID:
10404214
22.

A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator.

Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y.

EMBO J. 1999 May 4;18(9):2551-62.

23.

Transcription termination factor Rho contains three noncatalytic nucleotide binding sites.

Kim DE, Shigesada K, Patel SS.

J Biol Chem. 1999 Apr 23;274(17):11623-8.

24.

Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.

Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesada K, Ito Y.

Blood. 1999 Mar 15;93(6):1817-24.

PMID:
10068652
25.

The quaternary geometry of transcription termination factor rho: assignment by chemical cross-linking.

Horiguchi T, Miwa Y, Shigesada K.

J Mol Biol. 1997 Jun 20;269(4):514-28.

PMID:
9217257
26.

Redox regulation of the DNA binding activity in transcription factor PEBP2. The roles of two conserved cysteine residues.

Akamatsu Y, Ohno T, Hirota K, Kagoshima H, Yodoi J, Shigesada K.

J Biol Chem. 1997 Jun 6;272(23):14497-500.

27.
28.
29.

Structural and functional dissections of transcription termination factor rho by random mutagenesis.

Miwa Y, Horiguchi T, Shigesada K.

J Mol Biol. 1995 Dec 15;254(5):815-37.

PMID:
7500353
30.

Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain.

Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, Namba Y, Satake M, Ito Y.

Gene. 1995 Jul 4;159(2):245-8.

PMID:
7622058
31.

Subcellular localization of the alpha and beta subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF.

Lu J, Maruyama M, Satake M, Bae SC, Ogawa E, Kagoshima H, Shigesada K, Ito Y.

Mol Cell Biol. 1995 Mar;15(3):1651-61.

32.

Human cytoplasmic isoleucyl-tRNA synthetase: selective divergence of the anticodon-binding domain and acquisition of a new structural unit.

Shiba K, Suzuki N, Shigesada K, Namba Y, Schimmel P, Noda T.

Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7435-9.

33.

PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials.

Bae SC, Ogawa E, Maruyama M, Oka H, Satake M, Shigesada K, Jenkins NA, Gilbert DJ, Copeland NG, Ito Y.

Mol Cell Biol. 1994 May;14(5):3242-52.

34.

The Runt domain identifies a new family of heteromeric transcriptional regulators.

Kagoshima H, Shigesada K, Satake M, Ito Y, Miyoshi H, Ohki M, Pepling M, Gergen P.

Trends Genet. 1993 Oct;9(10):338-41. Review. No abstract available.

PMID:
8273148
35.

PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene.

Ogawa E, Maruyama M, Kagoshima H, Inuzuka M, Lu J, Satake M, Shigesada K, Ito Y.

Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6859-63.

36.

Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha.

Ogawa E, Inuzuka M, Maruyama M, Satake M, Naito-Fujimoto M, Ito Y, Shigesada K.

Virology. 1993 May;194(1):314-31.

PMID:
8386878
37.

Isolation of PEBP2 alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1.

Bae SC, Yamaguchi-Iwai Y, Ogawa E, Maruyama M, Inuzuka M, Kagoshima H, Shigesada K, Satake M, Ito Y.

Oncogene. 1993 Mar;8(3):809-14.

PMID:
8437866
38.

Human T cell L-plastin bundles actin filaments in a calcium-dependent manner.

Namba Y, Ito M, Zu Y, Shigesada K, Maruyama K.

J Biochem. 1992 Oct;112(4):503-7.

39.

Polyclonal and monoclonal antibodies monospecific to MMTV LTR orf protein produced in E. coli.

Haga S, Shigesada K, Namba Y, Tanaka H, Imai S, Morimoto J, Hiroishi S, Yamamoto H, Sarkar NH, Hilgers J.

Cancer Lett. 1992 Aug 31;65(3):201-7.

PMID:
1325284
41.
42.

Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer.

Kamachi Y, Ogawa E, Asano M, Ishida S, Murakami Y, Satake M, Ito Y, Shigesada K.

J Virol. 1990 Oct;64(10):4808-19.

43.

65-kilodalton protein phosphorylated by interleukin 2 stimulation bears two putative actin-binding sites and two calcium-binding sites.

Zu YL, Shigesada K, Nishida E, Kubota I, Kohno M, Hanaoka M, Namba Y.

Biochemistry. 1990 Sep 11;29(36):8319-24.

PMID:
2252891
44.

A ubiquitous repressor interacting with an F9 cell-specific silencer and its functional suppression by differentiated cell-specific positive factors.

Furukawa K, Yamaguchi Y, Ogawa E, Shigesada K, Satake M, Ito Y.

Cell Growth Differ. 1990 Mar;1(3):135-47.

45.
48.

The complete cDNA sequence for the premature form of growth hormone of the flounder Paralichthys olivaceus.

Mori H, Kimura T, Tsunenari T, Ogura T, Niki H, Ezaki B, Shigesada K, Hiraga S.

Nucleic Acids Res. 1989 May 25;17(10):3977. No abstract available.

49.

Regulatory effect of a synthetic CRP recognition sequence placed downstream of a promoter.

Morita T, Shigesada K, Kimizuka F, Aiba H.

Nucleic Acids Res. 1988 Aug 11;16(15):7315-32.

Supplemental Content

Loading ...
Support Center